Featured
Phase 1 study of IO-202 in combination with azacitidine currently enrolling newly diagnosed CMML patients
Collaboration to evaluate IO-108 in combination with atezolizumab (Tecentriq®) and bevacizumab (Avastin®) as a potential first-line therapy for hepatocellular carcinoma